Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

Astatine-211-parthanatine ([(211)At]PTT) is an alpha-emitting radiopharmaceutical therapeutic that targets poly(adenosine-diphosphate-ribose) polymerase 1 (PARP1) in cancer cells. High-risk neuroblastomas exhibit among the highest PARP1 expression across solid tumors. In this study, we evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Makvandi, Mehran, Samanta, Minu, Martorano, Paul, Lee, Hwan, Gitto, Sarah B., Patel, Khushbu, Groff, David, Pogoriler, Jennifer, Martinez, Daniel, Riad, Aladdin, Dabagian, Hannah, Zaleski, Michael, Taghvaee, Tara, Xu, Kuiying, Lee, Ji Youn, Hou, Catherine, Farrel, Alvin, Batra, Vandana, Carlin, Sean D., Powell, Daniel J., Mach, Robert H., Pryma, Daniel A., Maris, John M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671962/
https://www.ncbi.nlm.nih.gov/pubmed/36396952
http://dx.doi.org/10.1038/s42003-022-04209-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671962/
https://www.ncbi.nlm.nih.gov/pubmed/36396952
http://dx.doi.org/10.1038/s42003-022-04209-8

Ejemplares similares